# KDM6A Gene: Structure, Function, and Clinical Significance ## Key Takeaways - KDM6A (UTX) is a histone H3 lysine 27 (H3K27) demethylase, crucial for removing repressive chromatin marks and activating gene transcription, particularly at enhancers, and is a component of the COMPASS complex with MLL3/MLL4. - The gene escapes X-chromosome inactivation, leading to higher expression in females, which has significant implications for sex-biased disease susceptibility, such as increased risk for multiple sclerosis in females and differential survival outcomes in urothelial carcinoma. - Germline loss-of-function mutations in KDM6A cause Kabuki syndrome type 2 (KS2), a multisystem disorder characterized by distinct facial dysmorphism, skeletal abnormalities, and intellectual disability. - KDM6A is a bona fide tumor suppressor frequently mutated in various cancers (e.g., urothelial carcinoma, AML), where its loss impairs DNA repair pathways like homologous recombination, creating synthetic lethality with PARP inhibitors. - KDM6A's catalytic activity requires oxygen, making it sensitive to hypoxic conditions prevalent in tumors, and its dysfunction is implicated in metabolic disorders, cardiovascular disease, and neurodevelopmental conditions. - Therapeutic strategies for KDM6A-mutant cancers include exploiting synthetic lethality with PARP inhibitors and utilizing EZH2 inhibitors, while direct KDM6A inhibitors are being explored for cancers where it is overexpressed. --- ## Executive Summary & Key Metadata The KDM6A gene (Lysine Demethylase 6A), also widely known as UTX (Ubiquitously Transcribed Tetratricopeptide Repeat, X chromosome), encodes a histone H3 lysine 27 (H3K27) di- and tri-methyl demethylase. As a component of the COMPASS (Complex of Proteins Associated with Set1) and MLL3/MLL4 complexes, KDM6A functions as a master epigenetic gatekeeper that removes repressive chromatin marks to facilitate transcriptional activation. The gene is notable for its escape from X-chromosome inactivation, resulting in higher expression in females across multiple tissues, a feature with profound implications for sex-biased physiology and disease susceptibility. KDM6A is a bona fide tumor suppressor, frequently mutated in a wide spectrum of malignancies including urothelial carcinoma, acute myeloid leukemia (AML), esophageal squamous cell carcinoma, pancreatic cancer, and multiple myeloma. Germline loss-of-function mutations cause Kabuki syndrome type 2 (KS2), a congenital multisystem disorder. | **Attribute** | **Value** | |:---|:---| | **HGNC Symbol** | KDM6A | | **UniProt Accession** | O15550 | | **Representative PDB ID** | true (e.g., 3AVR, 3AVS, 3AVP for catalytic domain) | | **Chromosomal Locus** | Xp11.3 (GRCh38: X: 44,873,188–45,112,779) | | **Primary Molecular Function** | Histone H3K27me2/3 demethylase; transcriptional co-activator | | **Disease & Pathology Associations** | Kabuki syndrome type 2; Urothelial carcinoma; AML; Pancreatic cancer; Multiple myeloma; Esophageal squamous cell carcinoma; Congenital heart defects | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Architecture KDM6A is located on the short arm of the X chromosome at cytogenetic band Xp11.3. The gene spans approximately 239.6 kilobases (kb) of genomic DNA on the forward strand, encompassing 29 exons that produce a primary transcript of roughly 5,461 nucleotides coding for a protein of 1,401 amino acids. The genomic coordinates per GRCh38/hg38 assembly are chrX:44,873,188–45,112,779. The gene is highly conserved across vertebrates, with orthologs identified in mouse, pig, goat, and zebrafish, underscoring its fundamental role in development and cellular homeostasis. A defining genomic feature of KDM6A is its escape from X-chromosome inactivation (XCI). In female mammals, one X chromosome is transcriptionally silenced to achieve dosage compensation; however, approximately 15% of X-linked genes escape this silencing. KDM6A is a prototypical escapee, resulting in biallelic expression in females and monoallelic expression in males. This female-biased expression has been demonstrated at the mRNA and protein levels in numerous tissues, including immune cells, adipocytes, hepatocytes, and neurons. The Y-chromosome harbors a paralog, UTY (Ubiquitously Transcribed Tetratricopeptide Repeat, Y chromosome), which shares ~85% amino acid identity with KDM6A in the tetratricopeptide repeat (TPR) domain but lacks catalytic demethylase activity due to critical substitutions in the Jumonji C (JmjC) domain. This evolutionary arrangement creates a complex sex-specific functional landscape where females possess two active demethylase alleles, while males possess one demethylase allele (KDM6A) and one catalytically dead scaffold (UTY). ### 1.2 Promoter Architecture and Regulatory Elements The KDM6A promoter region is characterized by a large CpG island spanning the transcription start site (TSS), a feature common to housekeeping and developmentally regulated genes. The promoter lacks a canonical TATA box but contains multiple Sp1 binding sites and initiator elements that facilitate basal transcription. Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from ENCODE reveal that the promoter is marked by H3K4me3 and H3K27ac in most cell types, consistent with its ubiquitous expression. Transcriptional regulation of KDM6A is complex and cell-type specific. Several transcription factors have been shown to bind the KDM6A promoter and enhancer regions, including: - **YY1 (Yin Yang 1)**: A zinc-finger transcription factor that recruits KDM6A to target gene promoters, creating a positive autoregulatory loop. - **HIF-1α (Hypoxia-Inducible Factor 1 Alpha)**: Under hypoxic conditions, HIF-1α directly binds to hypoxia response elements (HREs) in the KDM6A locus, inducing its expression. This is part of a feedback mechanism where KDM6A itself senses oxygen levels via its JmjC domain, which requires molecular oxygen, Fe(II), and 2-oxoglutarate as cofactors. - **Estrogen Receptor α (ERα)**: In hormone-responsive tissues, ERα binding to distal enhancers promotes KDM6A expression, contributing to sex-specific gene regulation. ### 1.3 Alternative Splicing and Isoforms Alternative splicing generates multiple KDM6A transcript variants. The canonical transcript (ENST00000377967.8) encodes the full-length 1,401-amino acid protein. At least five additional splice isoforms have been cataloged in Ensembl, primarily differing in the 5' untranslated region (UTR) and exon 1 usage. A notable variant, ENST00000457432, lacks exon 4, resulting in an in-frame deletion of 42 amino acids within the first TPR domain. This isoform exhibits reduced protein stability and altered subcellular localization, though its physiological significance remains under investigation. Tissue-specific alternative promoter usage has been reported in the brain and testis, where a distal promoter drives expression of a shorter isoform lacking the N-terminal 120 amino acids. This isoform retains catalytic activity but lacks several protein-protein interaction motifs, suggesting context-dependent functional specialization. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Domain Organization The KDM6A protein (UniProt O15550) is a 1,401-amino acid polypeptide with a modular architecture comprising several distinct functional domains. From the N-terminus to the C-terminus, the domain organization is as follows: | **Domain** | **Residues (approx.)** | **Function** | |:---|:---|:---| | **TPR1–TPR6 (Tetratricopeptide Repeat)** | 1–350 | Protein-protein interactions; mediates binding to COMPASS complex components (e.g., ASH2L, RBBP5, WDR5) | | **Low Complexity Region** | 351–500 | Intrinsically disordered; contains nuclear localization signals | | **JmjC Domain (Catalytic Core)** | 880–1,150 | Histone demethylase activity; binds Fe(II) and 2-oxoglutarate; demethylates H3K27me2/3 | | **C-terminal Domain** | 1,150–1,401 | Interaction with transcription factors; nuclear receptor binding; contains a second NLS | ### 2.2 The TPR Domain: A Scaffold for Chromatin Complex Assembly The N-terminal region of KDM6A contains six tandem TPR motifs, each consisting of a 34-amino acid degenerate repeat that folds into a helix-turn-helix structure. TPR domains mediate protein-protein interactions, and in KDM6A, they serve as a docking platform for the assembly of the COMPASS complex. Structural studies using X-ray crystallography and cryo-electron microscopy have demonstrated that the TPR domain of KDM6A binds directly to the WD40-repeat protein WDR5, which in turn recruits RBBP5 and ASH2L to form the core COMPASS module. This interaction is essential for the recruitment of KDM6A to chromatin and for the stabilization of the entire complex. The TPR domain also mediates KDM6A's interaction with sequence-specific transcription factors. For example, KDM6A binds to p53, RB, and YY1 through its TPR repeats, enabling targeted recruitment to specific genomic loci. Mutations within the TPR domain, such as the G774E substitution reported in congenital heart disease, disrupt these interactions and impair KDM6A's transcriptional regulatory functions. ### 2.3 The JmjC Catalytic Domain: Mechanism of Demethylation The catalytic core of KDM6A resides in the Jumonji C (JmjC) domain, spanning approximately residues 880–1,150. This domain belongs to the Fe(II)- and 2-oxoglutarate (2OG)-dependent dioxygenase superfamily. The demethylation reaction proceeds via an oxidative mechanism: 1. **Substrate binding**: The JmjC domain recognizes H3K27me2/3 peptides, positioning the methylated lysine in the catalytic pocket. 2. **Cofactor coordination**: Fe(II) is coordinated by a conserved HxD/E...H motif (His1126, Asp1128, His1190 in KDM6A), while 2OG binds via a conserved RXS motif. 3. **Oxygen activation**: Molecular oxygen reacts with Fe(II) and 2OG to form a ferryl (Fe(IV)=O) intermediate, which hydroxylates the methyl group on H3K27. 4. **Demethylation**: The unstable hydroxymethyl intermediate spontaneously decomposes to formaldehyde, releasing the demethylated lysine and regenerating the enzyme. This mechanism requires molecular oxygen as a co-substrate, making KDM6A an oxygen sensor. Under hypoxic conditions, KDM6A catalytic activity is reduced, leading to accumulation of H3K27me3 and altered gene expression programs. This oxygen sensitivity has significant implications for tumor biology, where hypoxic microenvironments are common. The JmjC domain also contains a zinc-binding motif (Cys-X2-Cys-X17-Cys-X2-Cys) that stabilizes the overall fold. Mutations in this zinc-finger region, frequently observed in cancer, abrogate catalytic activity and lead to loss of KDM6A function. ### 2.4 Structural Insights from PDB Entries Several high-resolution crystal structures of the KDM6A JmjC domain have been deposited in the Protein Data Bank (PDB). Representative entries include: - **3AVR**: Human KDM6A JmjC domain (residues 879–1,401) in complex with 2OG and a H3K27me3 peptide, resolved at 2.3 Å. - **3AVS**: KDM6A JmjC domain with the inhibitor GSK-J1, demonstrating the structural basis of competitive inhibition. - **3AVP**: Apo form of the KDM6A catalytic domain. These structures reveal a double-stranded β-helix (DSBH) fold characteristic of the 2OG-dependent oxygenase family, with the active site positioned in a deep pocket that accommodates the methylated lysine side chain. The structures have been instrumental in structure-based drug design efforts targeting KDM6A. ### 2.5 Post-Translational Modifications KDM6A is subject to multiple post-translational modifications that regulate its stability, localization, and activity: - **Phosphorylation**: CDK1/cyclin B phosphorylates KDM6A at Ser486 and Ser490 during the G2/M phase of the cell cycle, promoting its nuclear export and degradation. This cell cycle-dependent regulation ensures proper mitotic progression. - **Ubiquitination**: The E3 ligase TRIM28 (KAP1) ubiquitinates KDM6A, targeting it for proteasomal degradation. Loss of TRIM28 in renal cell carcinoma leads to KDM6A accumulation and aberrant autophagy. - **Acetylation**: p300/CBP acetylates KDM6A at Lys632, enhancing its chromatin association and transcriptional activity. --- ### Interactive 3D Protein Visualizer [Interactive 3D Protein Visualizer: Load KDM6A (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O15550) *Explore the three-dimensional architecture of the KDM6A protein, including the TPR repeats, JmjC catalytic domain, and key mutation hotspots. The visualizer allows rotation, zoom, and highlighting of specific domains and residues.* --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Histone Demethylation and Chromatin Remodeling KDM6A's primary molecular function is the removal of di- and tri-methyl groups from lysine 27 of histone H3 (H3K27me2/3). This mark is associated with transcriptional repression and is deposited by the Polycomb Repressive Complex 2 (PRC2), whose catalytic subunit is EZH2. By erasing H3K27me2/3, KDM6A counteracts PRC2 activity and promotes a permissive chromatin state conducive to gene activation. The demethylase activity of KDM6A is targeted to specific genomic loci through its association with transcription factors and chromatin remodeling complexes. KDM6A is a core component of the COMPASS complex, which also contains the H3K4 methyltransferases MLL3 (KMT2C) and MLL4 (KMT2D). This dual enzymatic activity—H3K4 methylation by MLL3/4 and H3K27 demethylation by KDM6A—creates a coordinated switch from repressive to active chromatin at enhancers and promoters. ### 3.2 Regulation of Enhancer Activity and Cell Fate Determination KDM6A plays a critical role in the activation of poised enhancers during development and differentiation. Poised enhancers are marked by H3K4me1 and H3K27me3 and are transcriptionally silent but primed for activation. Upon differentiation signals, KDM6A is recruited to these enhancers, removes H3K27me3, and facilitates the recruitment of additional co-activators, leading to enhancer activation and target gene expression. In embryonic stem cells (ESCs), KDM6A is essential for the activation of developmental gene expression programs. Knockout of KDM6A in human induced pluripotent stem cells (iPSCs) results in genome-wide alterations in histone methylation at active and poised enhancers, with consequent activation of ectodermal gene expression pathways. This demonstrates KDM6A's role as a gatekeeper of cell fate decisions. ### 3.3 KDM6A in the COMPASS Complex and Transcriptional Co-activation Beyond its catalytic function, KDM6A serves as a scaffold within the COMPASS complex, stabilizing the association of MLL3/MLL4 with core subunits (WDR5, RBBP5, ASH2L, DPY30). This scaffolding function is independent of demethylase activity, as demonstrated by studies showing that catalytically dead KDM6A mutants can still support transcriptional activation of certain genes. This dual functionality—catalytic and non-catalytic—explains the context-dependent roles of KDM6A in different tissues and cancer types. ### 3.4 KDM6A and the Wnt/β-Catenin Signaling Pathway KDM6A modulates the Wnt/β-catenin pathway, a critical regulator of cell proliferation, differentiation, and tumorigenesis. In gastric cancer, KDM6A loss leads to activation of Wnt/β-catenin signaling, promoting epithelial-to-mesenchymal transition (EMT) and tumor progression. Mechanistically, KDM6A demethylates H3K27me3 at the promoter of SALL4, a transcription factor that activates Wnt target genes. Loss of KDM6A results in SALL4 silencing and aberrant Wnt activation. ### 3.5 KDM6A in DNA Damage Response and Genomic Stability Recent studies have uncovered a role for KDM6A in the DNA damage response (DDR). KDM6A is recruited to sites of DNA double-strand breaks (DSBs), where it demethylates H3K27me3 and facilitates the recruitment of DNA repair factors, including BRCA1 and RAD51. This function is particularly important for homologous recombination (HR) repair. Loss of KDM6A impairs HR, leading to genomic instability and increased sensitivity to PARP inhibitors. This synthetic lethal interaction has therapeutic implications for KDM6A-mutant cancers. ### 3.6 KDM6A in Metabolism and Metabolic Signaling KDM6A regulates metabolic pathways through epigenetic control of key metabolic genes: - **Lipid Metabolism**: In the liver, KDM6A controls cholesterol and lipoprotein metabolism through a sex-specific KDM6A-HNF4A-CREBH network. Loss of KDM6A in hepatocytes leads to dysregulated lipid metabolism and increased atherosclerosis susceptibility in males. - **Adipocyte Function**: KDM6A regulates mature adipocyte function and energy expenditure. Adipose-specific KDM6A knockout in mice leads to obesity and metabolic dysfunction, with sex-specific effects. - **Glucose Metabolism**: In pancreatic β-cells, KDM6A regulates insulin secretion by controlling the expression of genes involved in glucose sensing and insulin granule exocytosis. ### 3.7 KDM6A in Immune Cell Function and Inflammation KDM6A is a critical regulator of immune responses, with sex-specific implications: - **Macrophage Polarization**: KDM6A promotes M1 (pro-inflammatory) macrophage polarization while suppressing M2 (anti-inflammatory) polarization. In obesity, KDM6A expression in adipose tissue macrophages is reduced, contributing to metabolic inflammation. KDM6A also promotes IL-6 and IFN-β production in macrophages in response to viral infection. - **T Cell Function**: In CD4+ T lymphocytes, KDM6A regulates autoimmunity. Female-biased KDM6A expression in T cells contributes to the higher susceptibility of females to multiple sclerosis (MS). Deletion of Kdm6a in microglia of female mice ameliorates neuroinflammation and restores translatome profiles in an MS model. - **Microglia and Neuroinflammation**: KDM6A escape from XCI is detrimental to ischemic brains via IRF5 signaling, exacerbating neuroinflammation after stroke. In diabetic retinopathy, KDM6A deficiency in microglia/macrophages epigenetically silences Lcn2 expression and reduces photoreceptor dysfunction. ### 3.8 Protein-Protein Interaction Networks KDM6A participates in extensive protein-protein interaction networks. Key interactors identified through affinity purification-mass spectrometry (AP-MS) and yeast two-hybrid screens include: | **Interactor** | **Function** | **Reference** | |:---|:---|:---| | **WDR5** | COMPASS complex core subunit | | | **RBBP5** | COMPASS complex core subunit | | | **ASH2L** | COMPASS complex core subunit | | | **MLL3/KMT2C** | H3K4 methyltransferase | | | **MLL4/KMT2D** | H3K4 methyltransferase | | | **EZH2** | PRC2 catalytic subunit (antagonistic) | | | **p53** | Tumor suppressor; transcriptional regulation | | | **RB** | Retinoblastoma protein; cell cycle control | | | **YY1** | Transcription factor; chromatin architecture | | | **TRIM28** | E3 ligase; ubiquitination | | | **HIF-1α** | Hypoxia response | | | **S100A10** | Chemotherapy-induced KDM6A recruitment | | | **OCT4** | Pluripotency factor | | ### 3.9 Signaling Pathway Diagram ```mermaid flowchart TD A["Extracellular Signals"] --> B["Receptor Tyrosine Kinases"] B --> C["PI3K/AKT/mTORC1"] C --> D["KDM6A Expression/Activity"] E["Hypoxia"] --> F["HIF-1α Stabilization"] F --> D G["Chemotherapy"] --> H["S100A10 Upregulation"] H --> I["KDM6A Recruitment to OCT4 Promoter"] I --> J["Breast Cancer Stemness"] D --> K["H3K27me2/3 Demethylation"] K --> L["Chromatin Remodeling"] L --> M["Gene Activation"] M --> N["Differentiation Genes"] M --> O["Tumor Suppressor Genes"] M --> P["DNA Repair Genes"] M --> Q["Immune Response Genes"] D --> R["COMPASS Complex Assembly"] R --> S["H3K4 Methylation"] S --> M D --> T["Wnt/β-Catenin Regulation"] T --> U["SALL4 Expression"] U --> V["EMT/Metastasis"] D --> W["Metabolic Gene Regulation"] W --> X["Lipid Metabolism"] W --> Y["Glucose Metabolism"] W --> Z["Adipocyte Function"] ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Mutation Spectrum in Cancer KDM6A is among the most frequently mutated genes in several cancer types. The mutation spectrum is dominated by loss-of-function alterations, including nonsense, frameshift, and splice-site mutations, consistent with its role as a tumor suppressor. The frequency of KDM6A mutations varies by cancer type: | **Cancer Type** | **Mutation Frequency** | **Reference** | |:---|:---|:---| | **Urothelial Carcinoma (Bladder Cancer)** | 20–30% | | | **Acute Myeloid Leukemia (AML)** | 5–10% | | | **Esophageal Squamous Cell Carcinoma** | 10–15% | | | **Pancreatic Ductal Adenocarcinoma** | 5–10% | | | **Multiple Myeloma** | 5–10% | | | **Clear Cell Renal Cell Carcinoma** | 5–8% | | | **Triple-Negative Breast Cancer** | 3–5% | | | **Cutaneous Squamous Cell Carcinoma** | 10–15% | | ### 4.2 Recurrent Mutation Hotspots While KDM6A mutations are distributed throughout the coding region, several recurrent hotspots have been identified: - **R1146***: A recurrent nonsense mutation in the JmjC domain, resulting in a truncated protein lacking catalytic activity. This mutation is frequently observed in bladder cancer and AML. - **Q363***: A nonsense mutation in the low-complexity region, leading to loss of the entire C-terminal half of the protein. - **G774E**: A missense mutation in the TPR domain associated with congenital heart disease and neurodevelopmental disorders. This mutation disrupts protein-protein interactions and impairs KDM6A's transcriptional regulatory functions. - **Frameshift mutations in exon 5–10**: These mutations introduce premature stop codons and are common in urothelial carcinoma. ### 4.3 Kabuki Syndrome Type 2 (KS2) Germline loss-of-function mutations in KDM6A cause Kabuki syndrome type 2 (KS2; OMIM #300867), an X-linked dominant disorder. KS2 accounts for approximately 5–10% of Kabuki syndrome cases, with the majority caused by KMT2D mutations (KS1). The clinical features of KS2 include: - **Characteristic facial dysmorphism**: Long palpebral fissures, eversion of the lateral third of the lower eyelid, arched eyebrows, and prominent ears. - **Skeletal abnormalities**: Scoliosis, brachydactyly, and fifth-finger clinodactyly. - **Intellectual disability**: Variable severity, ranging from mild to moderate. - **Growth retardation**: Postnatal growth deficiency. - **Organ malformations**: Congenital heart defects, renal anomalies, and cleft palate. A three-generation Chinese pedigree with recurrent fetal Kabuki syndrome due to a KDM6A variant has been reported, highlighting the importance of genetic counseling for affected families. Additionally, a case of cystic biliary atresia with paucity of bile ducts and a KDM6A gene mutation has been described, expanding the phenotypic spectrum of KS2. ### 4.4 Congenital Hyperinsulinism and KDM6A Duplications KDM6A duplications have been identified in patients with congenital hyperinsulinemic hypoglycemia (HI). Genome and epigenetic analyses have been used to resolve the pathogenicity of these duplications, demonstrating that KDM6A copy number variations can cause HI as a presenting feature of Kabuki syndrome. ### 4.5 Sex-Specific Clinical Outcomes in Urothelial Carcinoma KDM6A mutations have sex-specific impacts on clinical outcomes in urothelial carcinoma (UC). A study of 2,438 patients with UC from seven independent cohorts found that KDM6A mutations were associated with gender-based differences in survival outcomes. Male patients with KDM6A mutations had worse overall survival compared to female patients, suggesting that the loss of the second functional allele in males (due to X-linked hemizygosity) confers a more aggressive phenotype. This sex bias is supported by studies in sex-reversed mice, which demonstrated that the X chromosome protects against bladder cancer in females via a KDM6A-dependent epigenetic mechanism. ### 4.6 KDM6A in Hematological Malignancies In AML, KDM6A mutations are associated with increased relapse risk and poor prognosis. A study of adult AML patients in histological remission found that KDM6A variants significantly increased the cumulative incidence of relapse. KDM6A mutations are also recurrently gained at relapse, suggesting that they contribute to therapy resistance and disease progression. In chronic myelogenous leukemia (CML), KDM6A promotes imatinib resistance through YY1-mediated transcriptional upregulation of TRKA, independent of its demethylase activity. ### 4.7 KDM6A in Metabolic and Cardiovascular Disease KDM6A dysfunction contributes to metabolic and cardiovascular disease: - **Hypertension**: Conditional renal tubule-specific deletion of KDM6A in mice causes hypertension, demonstrating a role for KDM6A in blood pressure regulation. KDM6A regulates renal sodium excretion by controlling the expression of sodium transporters. - **Cardiac Aging**: KDM6A regulates cardiac aging through induction of HoxC4-mediated ER stress. Cardiac-specific KDM6A knockout accelerates cardiac aging. - **Hypoxia-Induced Cardiomyocyte Apoptosis**: KDM6A protects against hypoxia-induced cardiomyocyte apoptosis via H3K27me3 demethylation of the Ncx gene. - **Atherosclerosis**: The sex-specific KDM6A-HNF4A-CREBH network controls lipoprotein cholesterol metabolism and atherosclerosis susceptibility. ### 4.8 KDM6A in Neurodevelopmental and Neurological Disorders Beyond Kabuki syndrome, KDM6A dysfunction is implicated in various neurological conditions: - **Congenital Heart Disease with Neurodevelopmental Disorders**: The G774E mutation causes congenital heart disease with various neurodevelopmental disorders. - **Spinal Cord Injury**: KDM6A deletion promotes recovery of spinal cord injury by epigenetically regulating vascular regeneration. Conversely, microRNA-145-mediated KDM6A downregulation enhances neural repair after spinal cord injury via the NOTCH2/Abcb1a axis. - **Alzheimer's Disease**: KDM6A expression is associated with a sex-disease interaction in activated microglia, suggesting a role in Alzheimer's disease pathogenesis. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Viral Oncoprotein Interactions KDM6A interacts with several viral oncoproteins that hijack the host epigenetic machinery to promote viral replication and cellular transformation: - **HPV E7**: The human papillomavirus (HPV) E7 oncoprotein binds to KDM6A and recruits it to viral promoters, where it demethylates H3K27me3 and activates viral gene expression. This interaction is essential for the HPV life cycle and contributes to HPV-induced carcinogenesis. - **EBV EBNA2**: The Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA2) interacts with KDM6A to activate viral and cellular genes involved in B-cell transformation. KDM6A is recruited to EBNA2 target genes, where it removes repressive H3K27me3 marks and facilitates transcriptional activation. - **KSHV LANA**: The Kaposi's sarcoma-associated herpesvirus (KSHV) latency-associated nuclear antigen (LANA) binds KDM6A to maintain viral latency by regulating the expression of viral lytic genes. ### 5.2 Bacterial Effectors and Immune Evasion KDM6A is involved in host immune responses to bacterial pathogens. In macrophages, KDM6A promotes the expression of pro-inflammatory cytokines, including IL-6 and IFN-β, in response to bacterial infection. Some bacterial pathogens have evolved mechanisms to subvert KDM6A function: - **Mycobacterium tuberculosis**: M. tuberculosis infection downregulates KDM6A expression in macrophages, suppressing the host immune response and promoting bacterial survival. - **Salmonella enterica**: Salmonella effectors can modulate host histone modifications, including H3K27me3, potentially by interfering with KDM6A activity. ### 5.3 KDM6A in Viral-Mediated Carcinogenesis KDM6A loss-of-function mutations cooperate with viral oncoproteins to drive carcinogenesis. In HPV-positive head and neck cancers, KDM6A mutations are more frequent than in HPV-negative tumors, suggesting a synergistic interaction between viral oncoproteins and KDM6A loss. Similarly, in EBV-associated gastric cancer, KDM6A mutations are enriched, contributing to the epigenetic dysregulation characteristic of these tumors. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 KDM6A as a Therapeutic Target The dual role of KDM6A as a tumor suppressor and a context-dependent oncogene creates complex therapeutic opportunities. In cancers where KDM6A is mutated and lost, therapeutic strategies focus on exploiting synthetic lethal interactions. In cancers where KDM6A is overexpressed and promotes tumor growth, direct inhibition of KDM6A enzymatic activity is being explored. ### 6.2 Synthetic Lethality with PARP Inhibitors Loss of KDM6A impairs homologous recombination (HR) repair, creating a synthetic lethal interaction with poly(ADP-ribose) polymerase (PARP) inhibitors. Preclinical studies in AML have demonstrated that KDM6A-deficient cells are highly sensitive to PARP inhibition, and this effect is potentiated by BCL2 blockade. This has led to clinical interest in using PARP inhibitors (e.g., olaparib, niraparib) for KDM6A-mutant cancers. ### 6.3 EZH2 Inhibitors KDM6A loss leads to increased H3K27me3 levels due to unopposed PRC2/EZH2 activity. This creates a dependency on EZH2 for transcriptional repression of tumor suppressor genes. EZH2 inhibitors (e.g., tazemetostat, GSK126) have shown efficacy in preclinical models of KDM6A-deficient bladder cancer and multiple myeloma. Tazemetostat is FDA-approved for epithelioid sarcoma and is being investigated for other KDM6A-mutant malignancies. ### 6.4 Direct KDM6A Inhibitors Several small-molecule inhibitors of KDM6A have been developed: - **GSK-J1/J4**: A competitive inhibitor of the JmjC domain that binds to the 2OG cofactor pocket. GSK-J4 is a cell-permeable prodrug of GSK-J1 and has shown anti-tumor activity in preclinical models. - **KDM6A-IN-1**: A selective inhibitor with improved potency and selectivity for KDM6A over KDM6B. - **Compound 5c**: A novel inhibitor that targets the KDM6A TPR domain, disrupting protein-protein interactions with COMPASS complex components. These inhibitors are being evaluated for the treatment of cancers where KDM6A is overexpressed, including prostate cancer and hepatocellular carcinoma. ### 6.5 KDM6A in Immunotherapy Response KDM6A loss affects the tumor immune microenvironment and responses to immunotherapy: - **Bladder Cancer**: KDM6A loss regulates differential responses to immune checkpoint therapy and chemotherapy through genomic and metabolic effects. KDM6A-mutant tumors exhibit distinct immune profiles that may predict response to PD-1/PD-L1 inhibitors. - **Pancreatic Cancer**: KDM6A loss recruits tumor-associated neutrophils and promotes neutrophil extracellular trap (NET) formation, creating an immunosuppressive microenvironment. - **Multiple Myeloma**: KDM6A regulates immune response genes, and its loss leads to decreased expression of antigen presentation and cytokine signaling genes. ### 6.6 KDM6A in Photodynamic Therapy Resistance KDM6A deficiency promotes 5-aminolevulinic acid-mediated photodynamic therapy (ALA-PDT) resistance in bladder cancer by suppressing ROS accumulation. This has implications for treatment selection in non-muscle-invasive bladder cancer. ### 6.7 KDM6A and Chemotherapy Resistance KDM6A loss is associated with resistance to multiple chemotherapeutic agents: - **Cabozantinib**: KDM6A deficiency promotes tumor progression and resistance to cabozantinib treatment in clear cell renal cell carcinoma. - **Cisplatin**: Artemisinin pre-treatment enhances cisplatin efficacy in high-grade urothelial carcinoma via reverse gene expression modulation of FGFR3, HRAS, P53, and KDM6A. - **Imatinib**: KDM6A promotes imatinib resistance in CML through YY1-mediated transcriptional upregulation of TRKA. ### 6.8 KDM6A in CRISPR-Based Gene Therapy The development of CRISPR-Cas9 gene editing technologies has opened new avenues for targeting KDM6A. In cancers where KDM6A is lost, gene therapy approaches aim to restore KDM6A expression. Conversely, in cancers where KDM6A is overexpressed, CRISPR-based gene disruption is being explored. However, these approaches remain in preclinical development. --- ## 7. Bioinformatic Resources & Database Accessions | **Database** | **Accession/ID** | **URL** | |:---|:---|:---| | **NCBI Gene** | 7403 | https://www.ncbi.nlm.nih.gov/gene/7403 | | **Ensembl** | ENSG00000147050 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000147050 | | **UniProt** | O15550 | https://www.uniprot.org/uniprotkb/O15550 | | **RCSB PDB** | 3AVR, 3AVS, 3AVP | https://www.rcsb.org/search?q=KDM6A | | **OMIM** | 300128 (gene), 300867 (KS2) | https://www.omim.org/entry/300128 | | **ClinVar** | KDM6A | https://www.ncbi.nlm.nih.gov/clinvar/?term=KDM6A%5Bgene%5D | | **COSMIC** | KDM6A | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=KDM6A | | **STRING** | KDM6A (O15550) | https://string-db.org/network/O155 ## Related Clinical & Scientific Guides * [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway) * [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway) * [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)